IPP Bureau
Aurigene bets big on CRDMO expansion with $100 million outlay
By IPP Bureau - April 28, 2026
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Ahmedabad hosts national conclave on urban pest and vector control strategies
By IPP Bureau - April 28, 2026
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease
By IPP Bureau - April 28, 2026
The submission is backed by positive results from the Phase 3 AFFIRM study
Essilor Stellest lens positioned as key breakthrough in myopia control in India
By IPP Bureau - April 28, 2026
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
AstraZeneca wins US nod for at-home lupus treatment in major shift for SLE care
By IPP Bureau - April 28, 2026
The approval was driven by data from the Phase III TULIP-SC trial
LVPEI launches Eye and Brain Centre in Hyderabad with support from D. E. Shaw India
By IPP Bureau - April 27, 2026
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Indian Immunologicals clocks all-time high revenue of Rs 1,586 crore in FY26
By IPP Bureau - April 27, 2026
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Prof. Gobardhan Das appointed to NITI Aayog; PM Modi commends his contributions to R&D
By IPP Bureau - April 27, 2026
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
Sun Pharma to acquire Organon in $11.75 billion all-cash deal
By IPP Bureau - April 27, 2026
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Alembic announces FDA final approval for Fingolimod capsules
By IPP Bureau - April 27, 2026
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
Nihilent unveils nSEPIA Beta to turn emotional wellness into measurable science
By IPP Bureau - April 27, 2026
nSEPIA aims to bring structure to an area long dominated by subjectivity
BMS–Pfizer expands Eliquis access through Cost Plus Drug setting $345 monthly price
By IPP Bureau - April 27, 2026
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
Zydus wins DCGI nod to launch Phase III trials of new anti-malarial drug Zintrodiazine
By IPP Bureau - April 27, 2026
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
.jpg "Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push")
Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push
By IPP Bureau - April 27, 2026
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Huwel Lifesciences, ASMS expand into Southeast Asia with Singapore partner
By IPP Bureau - April 27, 2026
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
